Log In
Print
BCIQ
Print
Print this Print this
 

CV9104

  Manage Alerts
Collapse Summary General Information
Company CureVac GmbH
DescriptionModified mRNA vaccine targeting 6 antigens overexpressed in prostate cancer
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationProstate cancer
Indication DetailsTreat castration-resistant prostate cancer (CRPC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today